Adds Plasmonics-based Modulation Technology and a Team with Deep Silicon Photonics Expertise to Advance Marvell's Optical Roadmap SANTA CLARA, Calif.--(BUSINESS WIRE)--Marvell Technology, Inc. (NASDAQ ...

Marvell has bought Polariton Technologies, a developer of high-speed, low-power plasmonics-based silicon photonics devices.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities ...

Glioblastoma remains a highly challenging malignancy with a pronounced tendency for recurrence. The hypoxic microenvironment is a key contributor to ...

Peptide-based signaling systems occupy a central position in modern biochemical inquiry due to their potential to interface ...

A 2026 product overview of how RevivaFlow Foot is described for burning feet, tingling, and circulation support - covering ...

Target identification is the first and perhaps most critical step in drug discovery and development. Although the human genome contains roughly 20,000 protein-coding genes, only about 4,500 are ...

Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate ...

Recent research has shown that non-invasive brain stimulation (NIBS), transcranial magnetic stimulation (TMS) in particular, can modulate core memory ...

Marvell Technology has announced the acquisition of Polariton Technologies (Credit: metamorworks/Shutterstock.com) ...

Transcranial alternating current stimulation (tACS) has emerged as a promising noninvasive brain stimulation technique for treating neuropsychiatric disorders. Unlike transcranial direct current ...

You will be redirected to our submission process. The quest for more efficient, compact, and intelligent optical systems for computing and communications has catalyzed a convergence of two ...